Crystalline forms of a bruton's tyrosine kinase inhibitor
US-9828383-B1 · Nov 28, 2017 · US
Crystalline forms of ibrutinib
US10183024B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10183024-B2 |
| Application number | US-201715827471-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 30, 2017 |
| Priority date | Dec 2, 2016 |
| Publication date | Jan 22, 2019 |
| Grant date | Jan 22, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides crystalline forms of Ibrutinib. Specific crystalline forms provided by the present invention include Ibrutinib Form APO-I, an anhydrous form; APO-II, a methyl benzoate solvate of Ibrutinib; and APO-IV, a methyl salicylate solvate of Ibrutinib.
First claim
Opening claim text (preview).
What is claimed is: 1. A crystalline form of Ibrutinib that is a solvate of Ibrutinib and methyl benzoate. 2. The solvate of claim 1 , wherein the molar ratio of Ibrutinib to methyl benzoate is approximately 1:0.5. 3. The solvate of claim 2 , wherein the solvate is characterized by a powder X-ray diffraction (PXRD) diffractogram comprising peaks, expressed in degrees 2θ (±0.2°), at 6.4°, 10.1° and 12.8°. 4. The solvate of claim 3 , characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 2θ (±0.2°), selected from the group consisting of: 13.8°, 17.6°, 18.4°, 19.4°, 20.4°, 21.0°, 21.7°, 23.2°, 24.1° and 24.9°. 5. The solvate of claim 3 , characterized by a PXRD diffractogram further comprising peaks, expressed in degrees 2θ (±0.2°), at 13.8°, 17.6°, 18.4°, 19.4°, 20.4°, 21.0°, 21.7°, 23.2°, 24.1° and 24.9°.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Ortho-condensed systems · CPC title
Crystalline forms, e.g. polymorphs · CPC title
- A61K31/519Primary
ortho- or peri-condensed with heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10183024B2 cover?
- The present invention provides crystalline forms of Ibrutinib. Specific crystalline forms provided by the present invention include Ibrutinib Form APO-I, an anhydrous form; APO-II, a methyl benzoate solvate of Ibrutinib; and APO-IV, a methyl salicylate solvate of Ibrutinib.
- Who is the assignee on this patent?
- Apotex Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).